TB-500 vs thymosin β-4: what the marketing blurs and the structural biology clarifies.
"TB-500" is one of the most heavily marketed research peptides, and one of the most misunderstood. It is not full-length thymosin β-4 (Tβ4). It is a synthetic acetylated fragment derived from the actin-binding region of Tβ4 — typically the residues around 17–23 — sold as an injectable RUO compound. Every substantive question about TB-500 starts with getting this distinction right.
- Full-length thymosin β-4 (Tβ4) is a naturally occurring 43-amino-acid G-actin-sequestering protein present in most mammalian cells.
- "TB-500" sold by research-chemical vendors is a synthetic fragment (commonly a 17-mer containing the LKKTETQ actin-binding motif), acetylated at the N-terminus to improve stability.
- The fragment retains some of Tβ4's in vitro actin-binding and angiogenic signaling, but is not bioequivalent to intact Tβ4.
- Human clinical trials of intact Tβ4 exist (wound healing, myocardial infarction, dry eye) but not of the TB-500 fragment.
- WADA prohibits Tβ4 (and by extension TB-500) at all times, in and out of competition, under S2.5 — "growth factors."
- FDA has not approved Tβ4 or TB-500 for human use. Compounding availability of TB-500 is restricted.
Thymosin β-4 — what the parent protein is
Thymosin β-4 is a 43-amino-acid β-thymosin: a small, highly conserved intracellular protein whose primary function is to sequester G-actin monomers in a 1:1 stoichiometry, preventing premature polymerization into F-actin filaments. By buffering the free G-actin pool, Tβ4 is a central regulator of cytoskeletal dynamics.
Beyond actin sequestration, intact Tβ4 has been shown in in vitro and in vivo rodent work to:
- Promote endothelial cell migration and angiogenesis (Bock-Marquette et al., Nature 2004).
- Inhibit inflammation via modulation of NF-κB and downstream cytokines.
- Mobilize progenitor cells to sites of cardiac and dermal injury.
Phase II clinical trials of intact Tβ4 — under the development name RGN-259 (ophthalmic) and as a systemic agent for venous stasis ulcers — have been published. None led to FDA approval, and the program has contracted over time.
TB-500 is a fragment, not the protein
Residues ~17–23 of Tβ4 (the LKKTETQ motif) contain the canonical actin-binding site. Synthetic peptides spanning this motif, acetylated to resist aminopeptidase degradation, exhibit actin-sequestering activity in biochemical assays. TB-500 as sold to the research market is typically a peptide of this class — the exact length and modifications vary by manufacturer.
Why does this matter? Because Tβ4's biological activity is not exhausted by its actin-binding. Intact Tβ4 presents additional functional surfaces that engage chemokine receptors and intracellular partners. A 17-residue fragment may replicate the in vitro actin-buffering effect without reproducing the full spectrum of in vivo Tβ4 biology. The marketing term "TB-500" papers over this distinction.
What the rodent evidence actually shows
Most of the pre-clinical TB-500 literature is in horse sports-medicine journals, veterinary literature, and a small number of rodent tissue-repair papers. Signals include:
- Tendon healing. Faster tendon-to-bone integration in rat Achilles transection models (several papers, 2010s).
- Wound closure. Accelerated dermal healing in rat full-thickness excisional wound models.
- Cardioprotection. Rodent post-MI work using intact Tβ4 (not specifically TB-500) shows reduced scar size and improved ejection fraction.
The key caveat: much of this literature is on full-length Tβ4, not on the TB-500 fragment. Vendor marketing often conflates the two, citing Tβ4 papers to support TB-500 claims.
Human data, such as it is
No peer-reviewed, placebo-controlled RCT of the TB-500 fragment in humans has been published. Published human trials used intact Tβ4 (RGN-259 in dry eye, RGN-352 in wound healing) with mixed or non-positive primary outcomes and no approvals. Anecdotal reports from athletes and the veterinary racing community drive most of the human interest, and none of that constitutes clinical evidence.
Regulatory and sport
- WADA (World Anti-Doping Agency). Thymosin β-4 is listed under class S2.5 ("growth factors, including but not limited to... TB-500") and prohibited at all times, in and out of competition.
- USEF / FEI (equestrian). Explicitly prohibited. Multiple high-profile equine positives have been prosecuted.
- FDA. No approved indication in humans. Not available through US compounding pharmacies for human administration.
Reconstitution math (typical 5 mg vial)
| BAC water added | Concentration | Per IU (U-100) | For 2.5 mg (common research dose in lit) |
|---|---|---|---|
| 1 mL | 5,000 mcg/mL | 50 mcg | 50 IU |
| 2 mL | 2,500 mcg/mL | 25 mcg | 100 IU (exceeds 1-mL syringe) |
| 5 mL | 1,000 mcg/mL | 10 mcg | 250 IU (split across multiple injections) |
Where to read further
- Bock-Marquette I, et al. "Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature 2004;432:466–72.
- Sosne G, et al. "Thymosin β4 mechanisms of action: from structure to clinical applications." Expert Opin. Biol. Ther. 2016;16(S1):S5–S11.
- WADA Prohibited List, current year. Category S2.5 "Growth factors and growth factor modulators."